Advagene Biopharma
Advagene Biotherapeutics is a biotechnology company focused on developing mucosal immunotherapy products. Their core technology is the LTh(αK) protein platform, which can be used with antigens to develop nasal spray vaccines or as a standalone immunotherapy. Their product pipeline includes nasal spray influenza vaccines, immunotherapy for allergic rhinitis and asthma, and nasal spray vaccines and immunotherapies for COVID-19. The company holds patents in multiple countries for its core technology. Their nasal spray influenza vaccine (AD07030) has completed Phase II clinical trials, demonstrating safety and efficacy, and aims to capture a significant share of the influenza vaccine market. Their immunotherapy for allergic diseases, AD17002-AI, has the potential to reduce or replace steroid use and has completed Phase I/II trials for allergic rhinitis.
Advagene Biopharma
Advagene Biotherapeutics is a biotechnology company focused on developing mucosal immunotherapy products. Their core technology is the LTh(αK) protein platform, which can be used with antigens to develop nasal spray vaccines or as a standalone immunotherapy. Their product pipeline includes nasal spray influenza vaccines, immunotherapy for allergic rhinitis and asthma, and nasal spray vaccines and immunotherapies for COVID-19. The company holds patents in multiple countries for its core technology. Their nasal spray influenza vaccine (AD07030) has completed Phase II clinical trials, demonstrating safety and efficacy, and aims to capture a significant share of the influenza vaccine market. Their immunotherapy for allergic diseases, AD17002-AI, has the potential to reduce or replace steroid use and has completed Phase I/II trials for allergic rhinitis.